Additional Information
Additional Information for Johnson & Johnson
This is a multi-location business.
- Headquarters
- One Johnson & Johnson Plaza, New Brunswick, NJ 08933-0001
- BBB File Opened:
- 3/9/1990
- Years in Business:
- 139
- Business Started:
- 1/1/1886
- Type of Entity:
- Corporation
- Alternate Business Name
- Rogaine
- Neutrogena
- Clear & Clean Advantage
- Business Management
- Consumer Care Center
- Contact Information
Principal
- Consumer Care Center
Customer Contact
- Consumer Care Center
- Additional Contact Information
Phone Numbers
- (800) 582-4048Other Phone
- (866) 742-0201Other Phone
- (800) 582-4048
- Additional Business Information
- Additional InfoThe official source for job postings and careers at Johnson & Johnson is the company website at http://www.careers.jnj.com/ .Government ActionsGovernment Action: BBB reports on known government actions involving business’ marketplace conduct:Consent Judgment
The following describes a government action that has been resolved by either a settlement or a decision by a court or administrative agency. If the matter is being appealed, it will be noted below.
On January 22, 2019, New York Attorney General Letitia James announced that she and 45 other Attorneys General across the country reached a $120 million Consent Judgment with Johnson & Johnson and DePuy Inc. to resolve allegations that the company unlawfully promoted its metal-on-metal hip implant devices, the ASR XL and the Pinnacle Ultamet.
The Attorneys General allege that DePuy engaged in unfair and deceptive practices in its promotion of the ASR XL and Pinnacle Ultamet hip implant devices by making misleading claims as to the longevity, also known as survivorship, of metal-on-metal hip implants. DePuy advertised that the ASR XL hip implant had a survivorship of 99.2 percent at three years when the National Joint Registry of England and Wales reported a 7 percent revision rate at three years. Similarly, DePuy promoted the Pinnacle Ultamet as having a survivorship of 99.8 percent and 99.9 percent survivorship at five years when the National Joint Registry of England and Wales reported a 2.2 percent 3-year-
Some patients who required hip implant revision surgery to replace a failed ASR XL or Pinnacle Ultamet implant experienced persistent groin pain, allergic reactions, tissue necrosis, as well as a build-up of metal ions in the blood. The ASR XL was recalled from the market in 2010. DePuy discontinued its sale of the Pinnacle Ultamet in 2013.
As part of the Consent Judgment, DePuy has agreed to reform how it markets and promotes its hip implants. Under the Consent Judgment, DePuy is required to:
- Base claims of survivorship, stability or dislocations on scientific information and the most recent dataset available from a registry for any DePuy hip implant device.
- Maintain a post market surveillance program and complaint handling program.
- Update and maintain internal product complaint handling operating procedures including training of complaint reviewers.
- Update and maintain processes and procedures to track and analyze product complaints that do not meet the definition of Medical Device Reportable Events.
- Maintain a quality assurance program that includes an audit procedure for tracking complaints regarding DePuy Products that do not rise to the level of a Medical Device Reportable Event but that may indicate a device-related serious injury or malfunction.
- Perform quarterly reviews of complaints and if a subgroup of patients is identified that has a higher incidence of adverse events than the full patient population, determine the cause and alter promotional practices as appropriate.
The investigation was led by Texas and South Carolina. In addition to New York, also participating in the settlement are Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, and Wisconsin.
Government ActionsGovernment Action: BBB reports on known government actions involving business’ marketplace conduct:Texas Attorney General Civil Medicaid Fraud LawsuitThe following describes a pending government action that has been formally brought by a government agency but has not yet been resolved. We are providing a summary of the governments allegations, which have not yet been proven.
On September 4, 2019, Texas Attorney General Ken Paxton announced that his office filed a civil Medicaid fraud lawsuit against pharmaceutical manufacturer Johnson & Johnson, and its subsidiary Janssen Pharmaceuticals, Inc., for misrepresentations made to the Texas Medicaid program about their opioid drug, Duragesic.
The State alleges the companies directed their sales representatives to deliver false and misleading messages about their fentanyl opioid drug to doctors in Texas, including Medicaid doctors. Sales representatives told doctors Duragesic had fewer side effects, worked better, and posed less risk of addiction than other opioids, despite FDA reprimands that the claims were false and misleading. As a result of these alleged misrepresentations, Johnson & Johnson obtained the benefit of taxpayer-funded Texas Medicaid reimbursement for Duragesic.
The matter is pending.
- Serving Area
- AK
- AL
- AR
- AS
- AZ
- CA
- CO
- CT
- DC
- DE
- FL
- GA
- GU
- HI
- IA
- ID
- IL
- IN
- KS
- KY
- LA
- MA
- MD
- ME
- MI
- MN
- MO
- MS
- MT
- NC
- ND
- NE
- NH
- NJ
- NM
- NV
- NY
- OH
- OK
- OR
- PA
- PR
- RI
- SC
- SD
- TN
- TX
- UT
- VA
- VI
- VT
- WA
- WI
- WV
- WY
- Business Categories
- Health and Wellness
Alerts
See What BBB Reports OnAlert
Government Action: BBB reports on known significant government actions involving business’ marketplace conduct:
The following describes a government action that has been resolved by either a settlement or a decision by a court or administrative agency. If the matter is being appealed, it will be noted below.
OLYMPIA April 22, 2019— Attorney General Bob Ferguson’s today announced that Johnson & Johnson will pay $9.9 million to avoid going to trial for misrepresentations and failure to include serious risks in the instructions and marketing materials for surgical mesh devices. Ferguson is the first state attorney general to file a lawsuit against Johnson & Johnson regarding surgical mesh devices.
Approximately 14,000 Washington women had these devices implanted. While precise information is not available, the Attorney General’s Office believes hundreds of those have been adversely impacted so far, ranging from having to go back for another procedure, to having their quality of life impacted dramatically.
In May 2016, Attorney General Ferguson filed a lawsuit against Johnson & Johnson asserting that the company failed to include several serious, life-altering risks associated with its surgical mesh devices in materials for patients and doctors.
Ferguson asserted that Johnson & Johnson omitted known risks from the devices’ marketing materials for patients and “Instructions for Use” packets for doctors. Instructions for Use inserts provide doctors with important information about a medical device. The instructions should include any risks or adverse reactions associated with the device or its use.
The trial was scheduled to begin today.
To avoid trial, Johnson & Johnson will pay $9.9 million. Today, Ferguson announced the payment will be used to assist women who received pelvic mesh implants. This is in addition to any recovery they receive in a personal injury lawsuit. Many lawsuits have been filed across the country regarding these devices.
The Attorney General’s Office will announce a formal claims process in the future. Due to privacy protections in law, the Attorney General’s Office does not know the names of the women implanted with surgical mesh in Washington state. Consequently, the Attorney General’s cannot reach out to affected women directly. If you would like a claims administrator to contact you, provide your contact information here.
In addition to paying $9.9 million, the resolution prohibits Johnson & Johnson from making unfair or deceptive statements regarding surgical mesh, including statements about risks associated with the devices. If the company learns about new, significant risks associated with its surgical mesh, it must disclose those risks. Johnson & Johnson’s promotional material must be truthful, accurate, and presented in a balanced way. Further, if Johnson & Johnson sponsors a study or research and cites that study or research in promotional materials, it must disclose its sponsorship.
During a deposition, Johnson & Johnson Global Head of Medical Affairs Piet Hinoul admitted that the company knew about the serious risks “from day 1”, but did not inform patients of the risks.
Johnson & Johnson is one of the largest manufacturers and sellers of surgical mesh devices in the U.S. It continues to sell four of the devices in Washington state.
Government Action: BBB reports on known significant government actions involving business’ marketplace conduct:
On October 17, 2019, Johnson & Johnson and its subsidiary Ethicon Endo agreed to pay $116.9 million to 41 states participating in a settlement involving the deceptive marketing of transvaginal surgical mesh devices.
Per the settlement, the companies also must adhere to requirements involving the labeling of devices, including warnings and precautions and adverse reactions, as well as promotions, health care provider training, sponsorship, clinical research, and monitoring and compliance.
The 41 states involved in the settlement are Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia and Wisconsin.
Contact Information
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-0001
Accreditation
This business is not BBB Accredited
Years in Business: 139
BBB Rating
BBB Business Profiles may not be reproduced for sales or promotional purposes.
BBB Business Profiles are provided solely to assist you in exercising your own best judgment. BBB asks third parties who publish complaints, reviews and/or responses on this website to affirm that the information provided is accurate. However, BBB does not verify the accuracy of information provided by third parties, and does not guarantee the accuracy of any information in Business Profiles.
When considering complaint information, please take into account the company's size and volume of transactions, and understand that the nature of complaints and a firm's responses to them are often more important than the number of complaints.
BBB Business Profiles generally cover a three-year reporting period. BBB Business Profiles are subject to change at any time. If you choose to do business with this business, please let the business know that you contacted BBB for a BBB Business Profile.
As a matter of policy, BBB does not endorse any product, service or business. Businesses are under no obligation to seek BBB accreditation, and some businesses are not accredited because they have not sought BBB accreditation.